公司概况 - Edgewise Therapeutics, Inc. 是一家专注于发现、开发和商业化创新治疗严重罕见肌肉疾病的临床阶段生物制药公司[52] 产品信息 - 公司的主要产品候选药物EDG-5506是一种口服的选择性快速肌纤维（II型）肌球蛋白小分子抑制剂，旨在解决杜兴氏肌营养不良（DMD）和贝克氏肌营养不良（BMD）等疾病的根本原因[52] 财务状况 - 公司自成立以来一直致力于发现、识别和开发潜在的产品候选药物，但至今尚未完成任何产品的开发，也没有产生任何收入，从未盈利[52] - 公司的研发费用在2023年第一季度达到了1,987.6万美元，较2022年同期增加了8,752万美元，主要是由于内部成本增加、临床项目费用增加以及药物发现和临床前费用增加[67] - 公司的一般和行政费用在2023年第一季度达到了582.8万美元，较2022年同期增加了212.6万美元，主要是由于员工相关成本增加和专业咨询费用增加[68] - 公司的利息收入在2023年第一季度达到了286.6万美元，较2022年同期增加了2,700万美元，主要是由于2023年第一季度市场证券余额的利率较高[69] - 截至2023年3月31日，公司的现金、现金等价物和可市场化证券总额为3.28亿美元[70] 现金流 - 2023年第一季度，公司经营活动中的现金流为净现金流出22,826,000美元[71] - 2023年第一季度，公司投资活动中的现金流为净现金流入49,042,000美元[72] - 2023年第一季度，公司融资活动中的现金流为净现金流入21,000美元[73] 资金需求 - 公司未来需要大量资金用于产品候选品的开发和运营资金[74] - 公司预计将继续承担作为上市公司运营的额外成本[75] - 公司需要大量额外资金来完成产品候选品的监管批准过程和建立销售、营销和分销基础设施[76] - 公司的未来资金需求将取决于多个因素，包括研发产品候选品的范围、进展、结果和成本[77] 风险提示 - 公司的长期资金需求包括租赁义务[83] - 公司是一家“小型报告公司”，可能继续依赖于对较小报告公司可用的某些披露要求的豁免[88]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40236 Edgewise Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 82-1725586 (State or other jurisdiction of (I.R.S. Employer incorpor ...

A Novel Approach to Tackling Rare Progressive Muscle Disorders 1 Corporate Presentation May 2022 Disclaimer 2 This presentation contains forward-looking statements that involve substantial risks and uncertainties of Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"). All statements other than statements of historical facts contained in this presentation, including statements regarding our future financial condition, results of operations, business strategy and plans, and objectives of management for ...

A Novel Approach to Tackling Rare Progressive Muscle Disorders Corporate Presentation May 2022 1 Disclaimer 2 This presentation contains forward-looking statements that involve substantial risks and uncertainties of Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"). All statements other than statements of historical facts contained in this presentation, including statements regarding our future financial condition, results of operations, business strategy and plans, and objectives of management for ...

| --- | |-------| | | | | | | CONFIDENTIAL Our vision is to improve the lives of patients and families suffering from rare muscle disorders NASDAQ: EWTX Forward-Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties of Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"). All statements other than statements of historical facts contained in this presentation, including statements regarding our future financial condition, results of oper ...